IOC Editorial & Medical Information TeamPrepared with more than 22 years of bariatric-centre experience and checked against the official sources listed below. See our review process.
Instructions from your own surgical or prescribing team take priority over this general guide. Contact local emergency care for severe or rapidly worsening symptoms.
Key takeaways
- Ozempic is authorised for type 2 diabetes; do not confuse its indication with Wegovy's weight-management authorisation.
- Semaglutide requires prescription, genuine regulated supply and clinical monitoring.
- The safest alternative depends on diagnosis, BMI, related disease and previous treatment.
Ozempic is a diabetes medicine
Ozempic contains semaglutide and is authorised in the European Union for adults with insufficiently controlled type 2 diabetes, alongside diet and exercise. Weight reduction may occur during treatment, but Ozempic’s authorised indication should not be confused with Wegovy, the semaglutide product authorised for weight management under defined conditions.
Why assessment matters
A prescription decision should consider the diagnosis, BMI, diabetes control, cardiovascular and eye history, digestive symptoms, other medicines and pregnancy plans. Brand availability or popularity is not a clinical indication.
Semaglutide for weight management is intended to accompany reduced-calorie nutrition, physical activity and multidisciplinary support—not to provide cosmetic weight loss without medical need.
Ozempic should not be used during pregnancy. If you think you may be pregnant, contact your prescriber promptly. Discuss any future pregnancy in advance so that treatment changes and diabetes care can be planned.
Side effects and safer access
Common effects include nausea, vomiting and diarrhoea. Ozempic information also highlights the possibility of worsening diabetic retinopathy in some people with diabetes.
- Use only a prescribed product from a regulated supply chain.
- Do not buy pens through social media or informal sellers; falsified products have been reported.
- Speak to the prescriber before surgery, anaesthesia or changing another diabetes medicine.
Sudden vision changes: do not wait for a routine appointment
NAION (non-arteritic anterior ischaemic optic neuropathy) is an optic-nerve condition that can cause loss of vision. EMA classifies it as a very rare side effect of semaglutide. It is distinct from diabetic retinopathy, which affects the retina.
Sudden loss of vision, including partial loss, or rapidly worsening eyesight needs urgent eye assessment or emergency care, even without pain. Tell the clinician that you use semaglutide. If NAION is confirmed, the treating clinician should discontinue semaglutide.
Other symptoms that need prompt help
Not every stomach symptom is a routine side effect. In January 2026, MHRA strengthened pancreatitis warnings for GLP-1 medicines, including semaglutide.
- Seek urgent medical care for severe abdominal pain that persists, especially if it spreads to the back, with or without vomiting. This can be a sign of pancreatitis.
- Get emergency help for breathing difficulty or swelling of the face, lips, tongue or throat.
- Contact your treating team promptly if vomiting prevents you from keeping fluids down or you develop signs of dehydration.
Find the official Ozempic patient leaflet
The EMA PDF below includes patient leaflets and instructions for different Ozempic strengths and devices. Use the section matching your prescribed pack; do not copy another product’s instructions.
This is an English-language EU document, not a Turkish leaflet or confirmation of availability or authorisation in Türkiye. Ask your pharmacist for the current local leaflet. Do not switch between Ozempic and Wegovy or change the dose without your prescriber.
Open the official EMA Ozempic patient leaflets (English PDF)
Alternatives are diagnosis-specific
Depending on the assessment, alternatives may include another authorised medicine, structured lifestyle treatment, endoscopic therapy or bariatric surgery. Each has different indications, risks, permanence and follow-up needs.
Compare long-term weight-management options
Review medication alongside endoscopic and bariatric pathways after a structured assessment.
Open treatment pageFrequently asked questions
Is Ozempic a weight-loss medicine?
Ozempic is authorised for type 2 diabetes in the EU. Wegovy is the semaglutide product authorised for weight management under defined conditions.
Can I buy Ozempic online without a prescription?
You should not. Use a prescription and regulated supply chain; falsified GLP-1 products have been reported.
What side effects are common?
Nausea, vomiting and diarrhoea are among the common gastrointestinal effects. Individual risks require prescriber review.
Should Ozempic be stopped before surgery?
Follow a specific instruction from the anaesthetic, surgical or prescribing team because guidance and personal risk vary.
What should I do if my vision changes suddenly?
Seek urgent eye assessment or emergency care for sudden vision loss, including partial loss, or rapidly worsening eyesight. Do not wait for a routine appointment; tell the clinician that you use semaglutide.
Sources
This article was checked against the following official clinical and regulatory sources at its latest update.
European Medicines Agency — OzempicEuropean Medicines Agency — WegovyEMA — Ozempic product information and patient leaflets (English PDF; updated 25 August 2026)WHO — Warning on falsified semaglutide medicines (20 June 2024)EMA — NAION classified as a very rare semaglutide side effect (June 2025)MHRA — Semaglutide and NAION (5 February 2026)MHRA — Strengthened warnings on acute pancreatitis (29 January 2026)
